Viking Therapeutics (NASDAQ: VKTX)
Q3 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2022-11-02 | ||||||
REV |
Q2 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.210 | -0.230 | -0.0200 | ||||
REV | 0 |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of Viking Therapeutics (NASDAQ: VKTX) through any online brokerage.
Other companies in Viking Therapeutics’s space includes: Macrogenics (NASDAQ:MGNX), Outlook Therapeutics (NASDAQ:OTLK), AVEO Pharmaceuticals (NASDAQ:AVEO), Vaxxinity (NASDAQ:VAXX) and Jounce Therapeutics (NASDAQ:JNCE).
The latest price target for Viking Therapeutics (NASDAQ: VKTX) was reported by SVB Leerink on Thursday, April 28, 2022. The analyst firm set a price target for 12.00 expecting VKTX to rise to within 12 months (a possible 232.41% upside). 2 analyst firms have reported ratings in the last year.
The stock price for Viking Therapeutics (NASDAQ: VKTX) is $3.61 last updated August 10, 2022, 8:00 PM UTC.
There are no upcoming dividends for Viking Therapeutics.
Viking Therapeutics’s Q3 earnings are confirmed for Wednesday, November 2, 2022.
There is no upcoming split for Viking Therapeutics.
Viking Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.